Verisk Q1 Results Top Estimates; Backs FY24 Outlook

RTTNews | 21 dias atrás
Verisk Q1 Results Top Estimates; Backs FY24 Outlook

(RTTNews) - Verisk Analytics, Inc. (VRSK), a data analytics and technology provider, reported Wednesday that net income attributable to Verisk for the first quarter soared to $219.6 million or $1.52 per share from $56.3 million or $0.37 per share in the prior-year quarter.

Income from continuing operations increased to $1.52 per share from $1.27 per share last year. Excluding items, adjusted earnings from continuing operations for the quarter were $1.63 per share, compared to $1.29 per share in the year-ago quarter.

Revenues for the quarter grew 8.0 percent to $704.0 million from $651.6 million in the same quarter last year. It was also up 6.9 percent on an organic constant currency basis.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.53 per share on revenues of $699.06 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2024, the company continues to project adjusted earnings in a range of $6.30 to $6.60 per share, on revenues between $2.84 billion and $2.90 billion.

The Street is currently looking for earnings of $6.51 per share on revenues of $2.88 billion for the year.

Last week, the company's Board of Directors approved a 15 percent higher cash dividend of 39 cents per share of common stock issued and outstanding, payable on June 28, 2024, to holders of record as of June 15, 2024.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Marcadores : VRSK
read more
Verisk Analytics Boosts FY23 Outlook As Q2 Results Top Estimates

Verisk Analytics Boosts FY23 Outlook As Q2 Results Top Estimates

Verisk Analytics, Inc. (VRSK), a data analytics and technology provider, reported Wednesday that net income attributable to Verisk for the second quarter was $196.9 million or $1.35 per share, compared to $197.7 million or $1.24 per share in the prior-year quarter.
RTTNews | 294 dias atrás
U.S. Existing Home Sales Unexpectedly Extend Pullback In April

U.S. Existing Home Sales Unexpectedly Extend Pullback In April

Existing home sales in the U.S. unexpectedly saw further downside in the month of April, according to a report released by the National Association of Realtors on Wednesday. NAR said existing home sales slumped by 1.9 percent to an annual rate of 4.14 million in April after tumbling by 3.7 percent to a revised rate of 4.22 million in March.
RTTNews | 4h 48min atrás
Hovnanian Enterprises Net Profit Rises 48.9%

Hovnanian Enterprises Net Profit Rises 48.9%

Homebuilder Hovnanian Enterprises Inc. (HOV) reported Wednesday that net income for the second quarter increased 48.9 percent to $50.8 million or $6.66 per share from $34.1 million or $4.47 per share in the prior-year quarter.
RTTNews | 5h 11min atrás
Anglo American And BHP Major Shareholder PIC Demands Substantial Revision Of BHP Proposal For Anglo

Anglo American And BHP Major Shareholder PIC Demands Substantial Revision Of BHP Proposal For Anglo

Public Investment Corp. or PIC, a major shareholder of both Anglo American plc (AAUKY.PK, AAL.L) and BHP Group (BHP), on Wednesday said it requires a meaningful revision of the current BHP proposal for Anglo American to "reflect both the embedded value of existing Anglo assets and the future optionality and benefits that BHP can derive, specifically from Anglo's unlisted assets."
RTTNews | 6h 7min atrás
Bay Street Likely To Open Lower

Bay Street Likely To Open Lower

Canadian shares are likely to open on a slightly negative note Wednesday morning as energy and materials sectors may find the going somewhat tough due to weak commodity prices.
RTTNews | 6h 56min atrás
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
RTTNews | 6h 59min atrás